CFTR and cystic fibrosis: Such an approach is currently unfolding successfully in the case of CF, where several small-molecule modulator drugs that bind to the mutant CFTR protein and affect its plasma membrane (PM) trafficking or function to produce a beneficial effect are now available to treat a wide variety of genotypes.